SG11201900654QA - Anti-kras-g12d t cell receptors - Google Patents
Anti-kras-g12d t cell receptorsInfo
- Publication number
- SG11201900654QA SG11201900654QA SG11201900654QA SG11201900654QA SG11201900654QA SG 11201900654Q A SG11201900654Q A SG 11201900654QA SG 11201900654Q A SG11201900654Q A SG 11201900654QA SG 11201900654Q A SG11201900654Q A SG 11201900654QA SG 11201900654Q A SG11201900654Q A SG 11201900654QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- maryland
- avenue
- pct
- kras
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 102100030708 GTPase KRas Human genes 0.000 abstract 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 abstract 1
- 101000986084 Homo sapiens HLA class I histocompatibility antigen, C alpha chain Proteins 0.000 abstract 1
- 235000013382 Morus laevigata Nutrition 0.000 abstract 1
- 244000278455 Morus laevigata Species 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662369883P | 2016-08-02 | 2016-08-02 | |
| PCT/US2017/044615 WO2018026691A1 (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900654QA true SG11201900654QA (en) | 2019-02-27 |
Family
ID=59564253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913959WA SG10201913959WA (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
| SG11201900654QA SG11201900654QA (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913959WA SG10201913959WA (en) | 2016-08-02 | 2017-07-31 | Anti-kras-g12d t cell receptors |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US10611816B2 (ja) |
| EP (2) | EP3494133B1 (ja) |
| JP (3) | JP6993402B2 (ja) |
| KR (1) | KR102527052B1 (ja) |
| CN (2) | CN118063591A (ja) |
| AU (2) | AU2017306038B2 (ja) |
| CA (1) | CA3032870A1 (ja) |
| DK (1) | DK3494133T3 (ja) |
| ES (1) | ES2928051T3 (ja) |
| HR (1) | HRP20221183T1 (ja) |
| HU (1) | HUE060121T2 (ja) |
| IL (2) | IL301894B1 (ja) |
| LT (1) | LT3494133T (ja) |
| PL (1) | PL3494133T3 (ja) |
| PT (1) | PT3494133T (ja) |
| RS (1) | RS63615B1 (ja) |
| SG (2) | SG10201913959WA (ja) |
| SI (1) | SI3494133T1 (ja) |
| WO (1) | WO2018026691A1 (ja) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018026691A1 (en) * | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t cell receptors |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| WO2019060349A1 (en) | 2017-09-20 | 2019-03-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | CLASS II HLA RESTRICTED T LYMPHOCYTE RECEPTORS AGAINST KRAS MUTATED |
| AU2019290127A1 (en) * | 2018-06-19 | 2021-01-28 | Biontech Us Inc. | Neoantigens and uses thereof |
| CN113631172A (zh) * | 2019-01-25 | 2021-11-09 | 宾夕法尼亚大学理事会 | 用于靶向突变型ras的组合物和方法 |
| CA3130618A1 (en) * | 2019-02-20 | 2020-08-27 | Fred Hutchinson Cancer Research Center | Binding proteins specific for ras neoantigens and uses thereof |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| CN112110995A (zh) * | 2019-06-19 | 2020-12-22 | 上海交通大学医学院 | 肿瘤新抗原多肽及其用途 |
| CN112760290A (zh) * | 2019-10-21 | 2021-05-07 | 郑州大学 | 携带突变的肿瘤驱动基因的干细胞及其用途 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| CA3160468A1 (en) * | 2019-11-05 | 2021-05-14 | Board Of Regents, The University Of Texas System | Hla restricted hormad1 t cell receptors and uses thereof |
| CA3164986A1 (en) | 2019-12-20 | 2021-06-24 | Instil Bio (Uk) Limited | Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof |
| EP4086281A4 (en) * | 2019-12-30 | 2024-02-14 | China Immunotech (Beijing) Biotechnology Co., Ltd | IMPROVED T-CELL RECEPTOR STAR AND ITS USE |
| US20230272038A1 (en) * | 2020-07-13 | 2023-08-31 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class ii-restricted drb t cell receptors against ras with g12d mutation |
| EP4251177A2 (en) * | 2020-11-25 | 2023-10-04 | Geneius Biotechnology, Inc. | Antigen specific t cells and methods of making and using same |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| TW202309071A (zh) | 2021-05-05 | 2023-03-01 | 德商英麥提克生物技術股份有限公司 | 特異性結合ｐｒａｍｅ之抗原結合蛋白 |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
| CN114920823B (zh) * | 2022-05-27 | 2023-10-17 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| WO2024020537A2 (en) * | 2022-07-22 | 2024-01-25 | Board Of Regents, The University Of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
| CN115850444A (zh) * | 2022-09-15 | 2023-03-28 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN117777270A (zh) * | 2022-09-29 | 2024-03-29 | 广州医科大学 | 一种t细胞受体(tcr)及其用途 |
| WO2024129720A2 (en) * | 2022-12-13 | 2024-06-20 | Biontech Us Inc. | T cell receptor constructs and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US20020150891A1 (en) * | 1994-09-19 | 2002-10-17 | Leroy E. Hood | Diagnostic and therapeutic compositions and methods which utilize the t cell receptor beta gene region |
| US7709002B1 (en) | 1996-04-19 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| AU2003265948B8 (en) | 2002-09-06 | 2009-09-03 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| CA2674445C (en) | 2007-01-12 | 2016-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Gp100-specific t cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| DK2618835T3 (en) * | 2010-09-20 | 2017-08-28 | Biontech Cell & Gene Therapies Gmbh | ANTIGEN-SPECIFIC T-CELL RECEPTORS AND T-CELL EPITOPES |
| WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| EP3766896A1 (en) * | 2011-09-15 | 2021-01-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| CN104080907A (zh) * | 2011-11-30 | 2014-10-01 | 日本国立癌症研究中心 | 诱导恶性干细胞 |
| KR20160013049A (ko) * | 2013-06-03 | 2016-02-03 | 노파르티스 아게 | 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물 |
| GB201313377D0 (en) * | 2013-07-26 | 2013-09-11 | Adaptimmune Ltd | T cell receptors |
| GB201314404D0 (en) * | 2013-08-12 | 2013-09-25 | Immunocore Ltd | T Cell Receptors |
| WO2016085904A1 (en) | 2014-11-26 | 2016-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mutated kras t cell receptors |
| SG10201913868XA (en) * | 2015-09-15 | 2020-03-30 | The United States Of America As Represented By The Secretary | T cell receptors recognizing hla-cw8 restricted mutated kras |
| WO2018026691A1 (en) * | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-kras-g12d t cell receptors |
-
2017
- 2017-07-31 WO PCT/US2017/044615 patent/WO2018026691A1/en unknown
- 2017-07-31 JP JP2019505220A patent/JP6993402B2/ja active Active
- 2017-07-31 AU AU2017306038A patent/AU2017306038B2/en active Active
- 2017-07-31 SI SI201731231T patent/SI3494133T1/sl unknown
- 2017-07-31 KR KR1020197005837A patent/KR102527052B1/ko active IP Right Grant
- 2017-07-31 IL IL301894A patent/IL301894B1/en unknown
- 2017-07-31 SG SG10201913959WA patent/SG10201913959WA/en unknown
- 2017-07-31 CA CA3032870A patent/CA3032870A1/en active Pending
- 2017-07-31 LT LTEPPCT/US2017/044615T patent/LT3494133T/lt unknown
- 2017-07-31 ES ES17749580T patent/ES2928051T3/es active Active
- 2017-07-31 DK DK17749580.1T patent/DK3494133T3/da active
- 2017-07-31 PT PT177495801T patent/PT3494133T/pt unknown
- 2017-07-31 SG SG11201900654QA patent/SG11201900654QA/en unknown
- 2017-07-31 EP EP17749580.1A patent/EP3494133B1/en active Active
- 2017-07-31 HU HUE17749580A patent/HUE060121T2/hu unknown
- 2017-07-31 RS RS20220894A patent/RS63615B1/sr unknown
- 2017-07-31 IL IL264425A patent/IL264425B2/en unknown
- 2017-07-31 HR HRP20221183TT patent/HRP20221183T1/hr unknown
- 2017-07-31 CN CN202410214235.4A patent/CN118063591A/zh active Pending
- 2017-07-31 CN CN201780059356.4A patent/CN109790211B/zh active Active
- 2017-07-31 EP EP22182473.3A patent/EP4159751A1/en active Pending
- 2017-07-31 US US16/321,899 patent/US10611816B2/en active Active
- 2017-07-31 PL PL17749580.1T patent/PL3494133T3/pl unknown
-
2020
- 2020-04-02 US US16/838,395 patent/US11208456B2/en active Active
-
2021
- 2021-06-11 US US17/345,390 patent/US11897933B2/en active Active
- 2021-12-03 US US17/541,619 patent/US11840561B2/en active Active
- 2021-12-09 JP JP2021199878A patent/JP7413338B2/ja active Active
-
2023
- 2023-09-21 AU AU2023233125A patent/AU2023233125A1/en active Pending
- 2023-12-27 JP JP2023221526A patent/JP2024045139A/ja active Pending
-
2024
- 2024-01-25 US US18/423,020 patent/US20240209059A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900654QA (en) | Anti-kras-g12d t cell receptors | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201903089RA (en) | Aav delivery of nucleobase editors | |
| SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201908658TA (en) | Nucleobase editors comprising nucleic acid programmable dna binding proteins | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201908023YA (en) | T cell receptors and immune therapy using the same against prame positive cancers | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
| SG11201811448RA (en) | Dihydropyranopyrimidines for the treatment of viral infections | |
| SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201908784TA (en) | Improved antigen binding receptor formats | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201806758VA (en) | Vcn enhancer compositions and methods of using the same | |
| SG11201806905UA (en) | Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers | |
| SG11201901790YA (en) | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201806392XA (en) | Personalized delivery vector-based immunotherapy and uses thereof | |
| SG11201901684XA (en) | Anti-dengue virus antibodies, polypeptides containing variant fc regions, and methods of use | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof |